Gynecologic cancer intergroup (GCIG) Consensus review for mucinous ovarian carcinoma

International Journal of Gynecological Cancer

Volumn 24, Issue 9, 2014, Pages S14-S19

  Ledermann, Jonathan A ^a   Luvero, Daniela ^a   Shafer, Aaron ^b   O'Connor, Dennis ^c   Mangili, Giorgia ^d   Friedlander, Michael ^e   Pfisterer, Jacobus ^f   Mirza, Mansoor R ^g   Kim, Jae Weon ^h   Alexandre, Jerome ⁱ   Oza, Amit ^j   Brown, Jubilee ^k  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HARTFORD HOSPITAL   (United States)

^c University of Louisville School of Medicine   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f Gynecologic Oncology Center Kiel   (Germany)

^g University of Copenhagen   (Denmark)

^h Seoul National University College of Medicine   (South Korea)

ⁱ HÔTEL DIEU   (France)

^j PRINCESS MARGARET HOSPITAL   (Canada)

^k UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Mucinous ovarian cancer; Mucinous tumor

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER RECURRENCE; CANCER SURGERY; COLLOID CARCINOMA; GENETICS; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MOLECULAR BIOLOGY; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ADENOCARCINOMA, MUCINOUS; CONSENSUS; FEMALE; MEDICAL SOCIETY; MULTIMODALITY CANCER THERAPY; ONCOLOGY; OVARIAN NEOPLASMS; PATHOLOGY;

ADENOCARCINOMA, MUCINOUS; COMBINED MODALITY THERAPY; CONSENSUS; FEMALE; HUMANS; MEDICAL ONCOLOGY; OVARIAN NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 84988915826     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000296     Document Type: Review

References (31)

1. Shimada M, Kigawa J, Ohishi Y, et al. Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol. 2009;113:331-334.
2. Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27:985-993.
3. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet. 2001;357:176-182.
4. Kelemen LE, Kobel M. Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma. Lancet Oncol. 2011;12:1071-1080.
5. Shappell HW, Riopel MA, Smith Sehdev AE, et al. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-Type mucinous and mixed cell-Type) tumors: Atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529-1541.
6. Collaborative Group on Epidemiological Studies of Ovarian C, Beral V, Gaitskell K, et al. Ovarian cancer and smoking: individual participant meta-Analysis including 28, 114 women with ovarian cancer from 51 epidemiological studies. Lancet Oncol. 2012;13:946-956.
7. Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27:281-292.
8. Chiesa AG, Deavers MT, Veras E, et al. Ovarian intestinal type mucinous borderline tumors: Are we ready for a nomenclature change? Int J Gynecol Pathol. 2010;29:108-112.
9. Frumovitz M, Schmeler KM, Malpica A, et al. Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol. 2010;117:491-496.
10. Lee KR, Scully RE. Mucinous tumors of the ovary: A clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with 'pseudomyxoma peritonei'. Am J Surg Pathol. 2000;24:1447-1464.
11. Rodriguez IM, Prat J. Mucinous tumors of the ovary: A clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas. Am J Surg Pathol. 2002;26:139-152.
12. Rechsteiner M, Zimmermann AK, Wild PJ, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013;95:235-241.
13. Anglesio MS, Kommoss S, Tolcher MC, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229:111-120.
14. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.
15. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
16. Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97:80-83.
17. Khunamornpong S, Suprasert P, Pojchamarnwiputh S, et al. Primary and metastatic mucinous adenocarcinomas of the ovary: Evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101:152-157.
18. Kelly PJ, Archbold P, Price JH, et al. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. J Clin Pathol. 2010;63:169-173.
19. Vang R, Gown AM, Barry TS, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: Analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006;30:1130-1139.
20. Cho YH, Kim DY, Kim JH, et al. Is complete surgical staging necessary in patients with stage I mucinous epithelial ovarian tumours? Gynecol Oncol. 2006;103:878-882.
21. Schmeler KM, Tao X, Frumovitz M, et al. Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol. 2010;116:269-273.
22. Lin JE, Seo S, Kushner DM, et al. The role of appendectomy for mucinous ovarian neoplasms. Am J Obstet Gynecol. 2013; 208:e41-e44.
23. Naik JD, Seligmann J, Perren TJ. Mucinous tumours of the ovary. J Clin Pathol. 2012;65:580-584.
24. Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003;95:105-112.
25. Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2005;97:436-441.
26. Hess V, A'Hern R, Nasiri N, et al. Mucinous epithelial ovarian cancer: A separate entity requiring specific treatment. J Clin Oncol. 2004;22:1040-1044.
27. Winter WE, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol. 2007;25:3621-3627.
28. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer. 2010;20:945-952.
29. Alexandre J, Ray-Coquard I, Selle F, et al. Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol. 2010;21:2377-2381.
30. Pignata S, Ferrandina G, Scarfone G, et al. Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. BMC Cancer. 2008;8:252.
31. Sato S, Itamochi H, Kigawa J, et al. Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: A potential treatment strategy. Cancer Sci. 2009;100:546-551.